Success Metrics

Clinical Success Rate
88.9%

Based on 32 completed trials

Completion Rate
89%(32/36)
Active Trials
0(0%)
Results Posted
6%(2 trials)
Terminated
4(11%)

Phase Distribution

Ph not_applicable
1
3%
Ph phase_2
23
61%
Ph phase_3
2
5%
Ph phase_1
12
32%

Phase Distribution

12

Early Stage

23

Mid Stage

2

Late Stage

Phase Distribution38 total trials
Phase 1Safety & dosage
12(31.6%)
Phase 2Efficacy & side effects
23(60.5%)
Phase 3Large-scale testing
2(5.3%)
N/ANon-phased studies
1(2.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

88.9%

32 of 36 finished

Non-Completion Rate

11.1%

4 ended early

Currently Active

0

trials recruiting

Total Trials

38

all time

Status Distribution
Completed(32)
Terminated(4)
Other(2)

Detailed Status

Completed32
Terminated4
unknown2

Development Timeline

Analytics

Development Status

Total Trials
38
Active
0
Success Rate
88.9%
Most Advanced
Phase 3

Trials by Phase

Phase 112 (31.6%)
Phase 223 (60.5%)
Phase 32 (5.3%)
N/A1 (2.6%)

Trials by Status

terminated411%
unknown25%
completed3284%

Recent Activity

0 active trials
Showing 5 of 38
completedphase_2

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019448
completedphase_2

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

NCT00019396
completedphase_2

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

NCT00020475
completedphase_1

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

NCT00003897
completedphase_1

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

NCT00470015
View all 38 trials

Clinical Trials (38)

Showing 20 of 38 trialsScroll for more
NCT00019448Phase 2

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed
NCT00019396Phase 2

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Completed
NCT00020475Phase 2

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Completed
NCT00003897Phase 1

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

Completed
NCT00470015Phase 1

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Completed
NCT00019682Phase 3

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

Completed
NCT00091338Phase 1

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed
NCT00019175Phase 1

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma

Completed
NCT00089063Phase 2

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Completed
NCT00003222Phase 2

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Completed
NCT00031733Phase 2

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Completed
NCT00006113Phase 2

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated
NCT00003339Phase 2

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Completed
NCT00005841Phase 1

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated
NCT00025181Phase 1

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Completed
NCT00003274Phase 2

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Completed
NCT00085189Phase 2

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Completed
NCT00010309Phase 1

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

Unknown
NCT00003568Phase 2

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed
NCT00003792Phase 1

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
38